Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish

Carina Beatrice VibeDepartment of Biosciences, University of Oslo, Oslo, Norway,

Federico FenaroliDepartment of Biosciences, University of Oslo, Oslo, Norway,

David PiresCentro De Patogénese Molecular—URIA/Instituto De Medicina Molecular, Instituto De Investigação Do Medicamento, iMed-ULisboa, Faculdade De Farmácia Da Universidade De Lisboa, Lisbon, Portugal,

Steven Ray WilsonDepartment of Chemistry, University of Oslo, Oslo, Norway, and

Vanya BogoevaDepartment of Molecular Biology of the Cell Cycle, Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria

Raja KalluruDepartment of Biosciences, University of Oslo, Oslo, Norway,

Martin SpethDepartment of Biosciences, University of Oslo, Oslo, Norway,

Elsa AnesCentro De Patogénese Molecular—URIA/Instituto De Medicina Molecular, Instituto De Investigação Do Medicamento, iMed-ULisboa, Faculdade De Farmácia Da Universidade De Lisboa, Lisbon, Portugal,

Gareth GriffithsDepartment of Biosciences, University of Oslo, Oslo, Norway,

Jon HildahlDepartment of Biosciences, University of Oslo, Oslo, Norway, Correspondence[email protected]

show all

Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date